We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.24B
AUM Growth
+$171M
Cap. Flow
+$215M
Cap. Flow %
2.98%
Top 10 Hldgs %
34.84%
Holding
226
New
18
Increased
74
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$49.6M
2
EXAS
Exact Sciences
EXAS
+$26.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$25.9M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$24.6M
5
MTEM
Molecular Templates, Inc.
MTEM
+$18.3M

Top Sells

Rank Stock Value
1
HALO icon
Halozyme
HALO
+$35.1M
2
PACB icon
Pacific Biosciences
PACB
+$25.7M
3
EVH icon
Evolent Health
EVH
+$20.6M
4
AKCA
Akcea Therapeutics Inc
AKCA
+$15.9M
5
MDT icon
Medtronic
MDT
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.98%
2 Industrials 0.6%
3 Technology 0.53%
4 Communication Services 0.41%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KOS icon
201
Kosmos Energy
KOS
$1.56B
$417K 0.01%
425,000
+365,000
+608% +$536K
TCOM icon
202
Trip.com Group
TCOM
$27.5B
$408K 0.01%
13,100
– –
MKTX icon
203
MarketAxess Holdings
MKTX
$4.15B
$396K 0.01%
822
– –
WAB icon
204
Wabtec
WAB
$51.1B
$396K 0.01%
6,400
– –
TW icon
205
Tradeweb Markets
TW
$21.3B
$394K 0.01%
6,800
– –
STZ icon
206
Constellation Brands
STZ
$22.2B
$390K 0.01%
2,059
– –
MKL icon
207
Markel Group
MKL
$25B
$389K 0.01%
400
– –
AZPN
208
DELISTED
ASPEN TECHNOLOGY INC
AZPN
$380K 0.01%
3,000
– –
SBUX icon
209
Starbucks
SBUX
$118B
$372K 0.01%
4,334
– –
AXP icon
210
American Express
AXP
$223B
$361K 0.01%
3,600
– –
AVNT icon
211
Avient
AVNT
$3.45B
$360K 0.01%
13,600
– –
SCI icon
212
Service Corp International
SCI
$11.4B
$359K 0.01%
8,500
– –
BKNG icon
213
Booking.com
BKNG
$138B
$342K ﹤0.01%
5,000
– –
FTNT icon
214
Fortinet
FTNT
$112B
$342K ﹤0.01%
14,500
– –
LYV icon
215
Live Nation Entertainment
LYV
$41.2B
$334K ﹤0.01%
6,200
– –
BLKB icon
216
Blackbaud
BLKB
$1.5B
$229K ﹤0.01%
4,107
– –
CVET
217
DELISTED
Covetrus, Inc. Common Stock
CVET
$37K ﹤0.01%
1,520
– –
BMRN icon
218
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-76,900
Closed -$9.48M
LEGN icon
219
Legend Biotech
LEGN
$4.3B
– –
-134,261
Closed -$5.71M
PTCT icon
220
PTC Therapeutics
PTCT
$6.37B
– –
-56,800
Closed -$2.88M
RGNX icon
221
Regenxbio
RGNX
$623M
– –
-41,000
Closed -$1.51M
STIM icon
222
Neuronetics
STIM
$120M
– –
-250,000
Closed -$483K
VIR icon
223
Vir Biotechnology
VIR
$1.47B
– –
-42,500
Closed -$1.74M
YI
224
111 Inc
YI
– –
-17,053
Closed -$1.08M
NARI
225
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-15,000
Closed -$727K
6 7 8
9
10

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q3 2020 Portfolio in Review

As of Q3 2020, Bellevue Group held 226 positions worth $7.24B, up 2.4% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q3 2020 filing shows 18 new, 74 increased, 41 reduced and 9 closed positions. Its largest new stake was Relay Therapeutics: 1,300,000 shares worth $55.4M. The largest sale was Halozyme, an estimated $35.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2020 buy was Relay Therapeutics: 1,300,000 shares worth $55.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2020, an estimated $25.9M increase.
  • Bellevue Group's biggest Q3 2020 reduction was Halozyme, cutting an estimated $35.1M.
  • Bellevue Group fully exited BioMarin Pharmaceuticals in Q3 2020, selling an estimated $9.48M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.24B portfolio in Q3 2020.
  • Bellevue Group opened 18 new positions and closed 9 in Q3 2020.
  • Bellevue Group's portfolio value rose 2.4% quarter-over-quarter to $7.24B.

Based on Bellevue Group's 13F filing for Q3 2020, filed 16 Nov 2020.